NEW YORK (GenomeWeb) – Roswell Park Cancer Institute subsidiary OmniSeq said today that it has received New York State Laboratory Evaluation Program approval for a 144-gene next-generation sequencing pan-cancer panel.

The OmniSeq Comprehensive Panel is designed to molecularly profile tumors in order to guide treatment decisions. It provides information on genes linked to more than 650 therapies and 850 clinical trials and can identify drugs that would not be appropriate for certain patients due to their genomic profile, according to the company.